title: Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Laura
authors.initials: L
authors.lastname: Cannella
authors.forename: Alessandra
authors.initials: A
authors.lastname: Serrao
authors.forename: Gioia
authors.initials: G
authors.lastname: Colafigli
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000378:metabolism*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015897:Comorbidity; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D011743:Pyrimidines; D002784:Cholesterol; D011505:Protein-Tyrosine Kinases; C498826:nilotinib